Comprehensive Psychiatric Care

Norwich, Connecticut 06360

0 studies enrolling now · 26 studies all time

What they study most

Alzheimer's Disease, Bipolar Disorder, Borderline Personality Disorder, Depression, Depressive Disorder, Major, Generalized Anxiety Disorder, Major Depressive Disorder, Migraine With or Without Aura, Obsessive Compulsive Disorder, Obsessive-Compulsive Disorder, Smoking Cessation, Treatment Resistant Depression

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder — Completed
• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder — Completed
• Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder — Completed
• Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD — Running, not enrolling
• A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder — Completed
• Randomized Trial of Adult Participants With Generalized Anxiety Disorder — Completed
• Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES) — Completed
• A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression — Stopped early
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder — Stopped early
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) — Completed
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression — Completed
• Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders. — Completed
• Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders — Completed
• A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) — Completed
• NeuroStar TMS Therapy System: Utilization and Outcomes — Completed
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease — Stopped early
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder — Completed
• Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression — Completed
• Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder — Stopped early